Citrate functionalized Mn3O4 in nanotherapy of hepatic fibrosis by oral administration | Zendy

Aniruddha Adhikari | Zendy; Nabarun Polley | Zendy; Soumendra Darbar | Zendy; Damayanti Bagchi | Zendy; Samir Kumar Pal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Citrate functionalized Mn₃O₄ in nanotherapy of hepatic fibrosis by oral administration

Author(s) -

Aniruddha Adhikari,

Nabarun Polley,

Soumendra Darbar,

Damayanti Bagchi,

Samir Kumar Pal

Publication year - 2016

Publication title -

future science oa

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.825

H-Index - 23

ISSN - 2056-5623

DOI - 10.4155/fsoa-2016-0029

Subject(s) - cirrhosis , in vivo , hepatic fibrosis , pharmacology , ccl4 , fibrosis , medicine , oral administration , antioxidant , liver fibrosis , chemistry , pathology , carbon tetrachloride , biochemistry , biology , microbiology and biotechnology , organic chemistry

Aim: To test the potential of orally administered citrate functionalized Mn 3 O 4 nanoparticles (C-Mn 3 O 4 NPs) as a therapeutic agent against hepatic fibrosis and associated chronic liver diseases. Materials & methods: C-Mn 3 O 4 NPs were synthesized and the pH dependent antioxidant mechanism was characterized by in vitro studies. CCl 4 intoxicated mice were orally treated with C-Mn 3 O 4 NPs to test its in vivo antioxidant and antifibrotic ability. Results: We demonstrated ultrahigh efficacy of the C-Mn 3 O 4 NPs in treatment of chronic liver diseases such as hepatic fibrosis and cirrhosis in mice compared with conventional medicine silymarin without any toxicological implications. Conclusion: These findings may pave the way for practical clinical use of the NPs as safe medication of chronic liver diseases associated with fibrosis and cirrhosis in human subjects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research